Bowel cancer drug appeal rejected
Campaigners have lost an appeal to make a bowel cancer drug widely available on the NHS. Charities Cancer backup and Bowel Cancer UK appealed against a decision by the health watchdog to reject the drug Erbitux (cetuximab) for use on the NHS. The National Institute for Health and Clinical Excellence (Nice) ruled last August that Erbitux was not cost-effective.